

[Open Peer Review on Qeios](#)

WT1-A10/AS01B Immunotherapeutic GSK2130579A

National Cancer Institute

Source

National Cancer Institute. *WT1-A10/AS01B Immunotherapeutic GSK2130579A*. NCI Thesaurus. Code C78865.

An immunotherapeutic consisting of the recombinant fusion protein WT 1-A10 combined with the adjuvant ASO1B with potential immunostimulating and antineoplastic activities. Upon administration, WT 1-A10/AS01B immunotherapeutic GSK2130579A WT 1 may induce a WT 1-specific cytotoxic T-lymphocyte (CTL) response against WT 1-expressing tumor cells, resulting in cell lysis and the inhibition of cellular proliferation. The tumor-associated antigen WT 1 (Wilms tumor protein-1) is overexpressed in most types of leukemia and in a variety of solid cancers. WT 1-A10 is a 292 amino acid recombinant fusion protein consisting of a 12-mer truncated tat sequence (leader sequence) and amino acids number 2-281 of the WT 1 sequence; ASO1B consists of a combination of the adjuvants monophosphoryl lipid A (MPL) and Q21.